Skip to content

Study · Randomized controlled trial · n = 92 · 1994

5 results

The hemostatic effects of desmopressin on patients who had total joint arthroplasty. A double-blind randomized trial.

Karnezis TA, Stulberg SD, Wixson RL, Reilly P

The Journal of bone and joint surgery. American volume1 Oct 1994Cited by 30 (Europe PMC)

PMID7929503 (opens in a new tab)DOI10.2106/00004623-199410000-00015 (opens in a new tab)PepBankPUB-07929503
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In total joint arthroplasty patients, desmopressin did not significantly decrease blood loss compared with placebo.

    In plain wordsAfter total joint replacement, desmopressin did not significantly reduce blood loss compared with placebo.

    Peptide
    Desmopressin
    Outcome
    No significant changeBlood loss
    Study

    n = 92

    Comparator
    Placebo
    Outcome group
    Blood Loss · Cardiovascular
    Studied dose
    0.03 microgram per kilogram · intravenousAs given in this study (human).

    Source sentences

    Summary
    Compared with the placebo, desmopressin did not significantly decrease blood loss or transfusion requirements, and it did not affect the postoperative platelet or fibrinogen levels or the bleeding time.
    3 context sentences
    Summary · context
    The effects of desmopressin on postoperative bleeding and postoperative transfusion requirements were studied in ninety-two hemostatically normal patients who had had an elective primary total hip or total knee arthroplasty.
    Summary · context
    The patients were randomized into either a placebo or a desmopressin group in a double-blind prospective clinical trial.
    Summary · context
    During closure of the wound, desmopressin (0.03 microgram per kilogram of body mass) or the placebo was infused into a peripheral vein over a twenty-minute period.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In total joint arthroplasty patients, desmopressin did not significantly decrease transfusion requirements compared with placebo.

    In plain wordsAfter total joint replacement, desmopressin did not significantly reduce transfusion needs compared with placebo.

    Peptide
    Desmopressin
    Outcome
    No significant changeTransfusion requirements
    Study

    n = 92

    Comparator
    Placebo
    Outcome group
    Blood Transfusion · Cardiovascular
    Studied dose
    0.03 microgram per kilogram · intravenousAs given in this study (human).

    Source sentences

    Summary
    Compared with the placebo, desmopressin did not significantly decrease blood loss or transfusion requirements, and it did not affect the postoperative platelet or fibrinogen levels or the bleeding time.
    3 context sentences
    Summary · context
    The effects of desmopressin on postoperative bleeding and postoperative transfusion requirements were studied in ninety-two hemostatically normal patients who had had an elective primary total hip or total knee arthroplasty.
    Summary · context
    The patients were randomized into either a placebo or a desmopressin group in a double-blind prospective clinical trial.
    Summary · context
    During closure of the wound, desmopressin (0.03 microgram per kilogram of body mass) or the placebo was infused into a peripheral vein over a twenty-minute period.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In total joint arthroplasty patients, desmopressin did not affect postoperative platelet levels compared with placebo.

    In plain wordsAfter total joint replacement, desmopressin did not change platelet levels compared with placebo.

    Peptide
    Desmopressin
    Outcome
    No significant changePostoperative platelet levels
    Study

    n = 92

    Comparator
    Placebo
    Outcome group
    Bleeding and clotting · Cardiovascular
    Studied dose
    0.03 microgram per kilogram · intravenousAs given in this study (human).

    Source sentences

    Summary
    Compared with the placebo, desmopressin did not significantly decrease blood loss or transfusion requirements, and it did not affect the postoperative platelet or fibrinogen levels or the bleeding time.
    3 context sentences
    Summary · context
    The effects of desmopressin on postoperative bleeding and postoperative transfusion requirements were studied in ninety-two hemostatically normal patients who had had an elective primary total hip or total knee arthroplasty.
    Summary · context
    The patients were randomized into either a placebo or a desmopressin group in a double-blind prospective clinical trial.
    Summary · context
    During closure of the wound, desmopressin (0.03 microgram per kilogram of body mass) or the placebo was infused into a peripheral vein over a twenty-minute period.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In total joint arthroplasty patients, desmopressin did not affect postoperative fibrinogen levels compared with placebo.

    In plain wordsAfter total joint replacement, desmopressin did not change fibrinogen levels compared with placebo.

    Peptide
    Desmopressin
    Outcome
    No significant changePostoperative fibrinogen levels
    Study

    n = 92

    Comparator
    Placebo
    Outcome group
    Bleeding and clotting · Cardiovascular
    Studied dose
    0.03 microgram per kilogram · intravenousAs given in this study (human).

    Source sentences

    Summary
    Compared with the placebo, desmopressin did not significantly decrease blood loss or transfusion requirements, and it did not affect the postoperative platelet or fibrinogen levels or the bleeding time.
    3 context sentences
    Summary · context
    The effects of desmopressin on postoperative bleeding and postoperative transfusion requirements were studied in ninety-two hemostatically normal patients who had had an elective primary total hip or total knee arthroplasty.
    Summary · context
    The patients were randomized into either a placebo or a desmopressin group in a double-blind prospective clinical trial.
    Summary · context
    During closure of the wound, desmopressin (0.03 microgram per kilogram of body mass) or the placebo was infused into a peripheral vein over a twenty-minute period.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In total joint arthroplasty patients, desmopressin did not affect bleeding time compared with placebo.

    In plain wordsAfter total joint replacement, desmopressin did not change bleeding time compared with placebo.

    Peptide
    Desmopressin
    Outcome
    No significant changeBleeding time
    Study

    n = 92

    Comparator
    Placebo
    Outcome group
    Bleeding and clotting · Cardiovascular
    Studied dose
    0.03 microgram per kilogram · intravenousAs given in this study (human).

    Source sentences

    Summary
    Compared with the placebo, desmopressin did not significantly decrease blood loss or transfusion requirements, and it did not affect the postoperative platelet or fibrinogen levels or the bleeding time.
    3 context sentences
    Summary · context
    The effects of desmopressin on postoperative bleeding and postoperative transfusion requirements were studied in ninety-two hemostatically normal patients who had had an elective primary total hip or total knee arthroplasty.
    Summary · context
    The patients were randomized into either a placebo or a desmopressin group in a double-blind prospective clinical trial.
    Summary · context
    During closure of the wound, desmopressin (0.03 microgram per kilogram of body mass) or the placebo was infused into a peripheral vein over a twenty-minute period.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.